Sorrento Therpt (SRNE)
$8.89
0.41 (4.41%)
SRNE Stock Quote Delayed 30 Minutes
Previous Close
-
Market Cap
1.03B
PE Ratio
44.45
EPS
0.2
Volume (Avg. Vol.)
13.08M
Day's Range
8.88 - 9.49
52-Week Range
1.45 - 19.39
Dividend & Yield
N/A (N/A)
SRNE Stock Predictions, Articles, and Sorrento Therpt News
Sorrento Therapeutics Isn’t the Way to Play Covid Stocks
There are several established biotech companies for investors to consider but they should avoid buying SRNE stock.
Don’t Give Up on Sorrento Therapeutics Stock Just Yet
While Sorrento Therapeutics has an impressive pipeline, it needs to bring something to market. The clock is ticking on SRNE stock.
3 Reasons to Inject Your Portfolio with Sorrento Therapeutics
With the novel coronavirus becoming an extended reality for us, no one platform offers a comprehensive solution. And that’s why Sorrento Therapeutics’ all-in pivot bodes well for SRNE stock.
Sorrento Stock Needs to Show Results
Sorrento has a ton of interesting clinical work going on. But with Covid-19 science rapidly advancing, SRNE stock doesn't have much time left to cash in.
Sorrento Stock Investors Should Play Powerball Instead
SRNE stock buyers beware. Company management has long targeted unsuspecting biotech investors in never-ending game of fundraising.
The Risk Is Worth the Reward for Sorrento Stock
While SRNE stock carries a lot of risk, the potential reward from one of its coronavirus plays panning out makes it attractive among biotech stocks.
The Risk-to-Reward Proposition for Sorrento Has Gone Bad
Sorrento Therapeutics shareholders witnessed SRNE stock gain 70% in the past month. The risk-to-reward proposition has gone from good to bad.
Does Sorrento Therapeutics Meet the ‘SAD’ Criteria for Vaccines?
If you love to gamble, SRNE stock is the right one for you. Few other companies, if any, have pivoted as hard as Sorrento did toward Covid-19. Just be aware of the risks.
Investors Should Proceed With Caution in Sorrento Stock
After running up more than 1,000% this year, Sorrento Therapeutic's stock has pulled back with the broader market in September and is now down 43% from its peak. This retrenchment has spooked many investors. However, patient investors who are willing to stick with Sorrento, or those who buy at the current price, may be rewarded with big future returns.
Sorrento Therapeutics Is Simply Running Out of Time
SRNE stock is up over 200% because the company is taking several bites at the Covid-19 apple. However time is not on the company's side.
Sorrento’s Covid-19 Portfolio Makes It a Top Biotech Stock
Sorrento's multi-pronged approach makes SRNE stock a compelling bet for investors looking to expand their portfolios.
FDA Clearance Means It’s Go Time for Sorrento Therapeutics
It's a great time to be long SRNE stock as the company's ambitious Covid-19 treatment clinical trials take a giant step forward for Sorrento.
Why Investors Should Take a Serious, Bullish Look on Sorrento
Bears are waging a heavy and crowded bet against SRNE stock, but more good news could send the stock higher.
FDA Approval Highlights High-Risk Case for Sorrento Therapeutics Stock
SRNE stock can benefit from multiple efforts in the fight against the novel coronavirus. Risks are real, but the rewards are as well.
Tread Carefully, But Sorrento Stock Could Continue to Bounce Back
So, what's the call here? If you have a high risk tolerance, and are looking for a short-term pandemic play, SRNE stock today may be worth the risk. Just don't bet the ranch.
Is Sorrento Stock Really Worth the Speculation?
Sorrento has some potential positive catalysts, especially its Covid-19 diagnostic test. But SRNE stock is really just for the speculative part of your portfolio.
Sorrento Therapeutics Fails the Test as a Covid-19 Value Play
Lack of a track record, a lagging Covid-19 test project and executive turmoil make SRNE stock a coronavirus play to avoid.
SRNE Stock: Sorrento Therapeutics Pops on Plans to Launch Drug Trials
Sorrento Therapeutics just announced plans to launch human trials of its antibody drug. Here's why else SRNE stock is rallying.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
A
